2022
Polypharmacy and medical intensive care unit (MICU) admission and 10-year all-cause mortality risk among hospitalized patients with and without HIV
Gordon KS, Crothers K, Butt AA, Edelman EJ, Gibert C, Pisani MM, Rodriguez-Barradas M, Wyatt C, Justice AC, Akgün KM. Polypharmacy and medical intensive care unit (MICU) admission and 10-year all-cause mortality risk among hospitalized patients with and without HIV. PLOS ONE 2022, 17: e0276769. PMID: 36302039, PMCID: PMC9612570, DOI: 10.1371/journal.pone.0276769.Peer-Reviewed Original ResearchConceptsMedical intensive care unit admissionIntensive care unit admissionCare unit admissionMICU admissionSeverity of illnessHazard ratioHIV statusUnit admissionCause mortalityHospitalized patientsElectronic health record cohortLevel of polypharmacyRetrospective cohort studyCause mortality riskCohort studyHIV infectionCox regressionPolypharmacyMortality riskFiscal year 2009AdmissionPatientsMortalitySubstance useStrong associationEpigenetic Age Acceleration Markers Are Associated With Physiologic Frailty and All-Cause Mortality in People With Human Immunodeficiency Virus
Oursler KK, Marconi VC, Wang Z, Xu K, Montano M, So-Armah K, Justice AC, Sun YV. Epigenetic Age Acceleration Markers Are Associated With Physiologic Frailty and All-Cause Mortality in People With Human Immunodeficiency Virus. Clinical Infectious Diseases 2022, 76: e638-e644. PMID: 35970820, PMCID: PMC10169393, DOI: 10.1093/cid/ciac656.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusPhysiologic frailtyVACS IndexCause mortalityMortality discriminationImmunodeficiency virusAge accelerationEpigenetic age accelerationVeterans Aging Cohort Study (VACS) IndexWhite blood cell samplesVACS Index 2.0VACS Index scoreNon-Hispanic blacksIntrinsic epigenetic age accelerationExtrinsic epigenetic age accelerationEpigenome-wide DNA methylationBlood cell samplesHazard ratioOne-year increaseCox regressionMean ageC-statisticIndex scoreMortalityStudy indices
2020
All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factors
Gordon K, Manhapra A, Crystal S, Dziura J, Edelman E, Skanderson M, Kerns R, Justice A, Tate J, Becker W. All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factors. Drug And Alcohol Dependence 2020, 216: 108291. PMID: 33011662, PMCID: PMC7644145, DOI: 10.1016/j.drugalcdep.2020.108291.Peer-Reviewed Original ResearchConceptsMorphine equivalent daily doseCause mortalityLong-term opioid therapyTime-updated Cox regressionStrong dose-response relationshipUnnatural deathsEquivalent daily doseDose-response relationshipOpioid doseOpioid therapyUninfected patientsOpioid useDaily doseCox regressionMortality outcomesTherapy doseHigh doseMale veteransOverdose fatalitiesOverdose mortalityPLWHMortalityHIVPatientsDoseDifferences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma
Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Richards K, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Re V. Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 71-78. PMID: 31575557, PMCID: PMC6980754, DOI: 10.1158/1055-9965.epi-19-0503.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesCarcinoma, HepatocellularFemaleHepatectomyHIV InfectionsHospitals, VeteransHumansImmunologic SurveillanceKaplan-Meier EstimateLiverLiver CirrhosisLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm StagingRetrospective StudiesRisk FactorsTreatment OutcomeUnited StatesConceptsBarcelona Clinic Liver Cancer stageHIV statusHepatocellular carcinomaUninfected patientsHIV infectionTumor characteristicsUninfected personsPathology reportsVeterans Aging Cohort StudyLiver tissue samplingCohort of HIVMultivariable Cox regressionAdvanced hepatic fibrosisAging Cohort StudyLiver Cancer stageRisk of deathBackground hepatic parenchymaCohort studyHazard ratioLymphovascular invasionBCLC stageImproved survivalCox regressionHistologic featuresHepatic fibrosis
2018
Brief Report
Yanik EL, Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Horberg MA, Moore RD, Mathews WC, Justice AC, Hessol NA, Mayor AM, Gill MJ, Brooks JT, Sun J, Althoff KN, Engels EA, Silverberg MJ, Dubrow R. Brief Report. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 499-504. PMID: 29771785, PMCID: PMC6037538, DOI: 10.1097/qai.0000000000001719.Peer-Reviewed Original ResearchConceptsMelanoma incidenceAntiretroviral therapyGeneral populationMelanoma riskNorth American AIDS Cohort CollaborationRelationship of immunosuppressionWhite general populationHIV RNA levelsStandardized incidence ratiosCutaneous melanoma incidenceUltraviolet B exposureHigher melanoma incidenceHigh UVB exposureCohort CollaborationSkin surveillanceCD4 countHIV RNAImmune dysfunctionIncidence ratiosCox regressionHIV replicationRisk factorsCalendar periodWhite raceClinical care
2017
Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada
Dubrow R, Qin L, Lin H, Hernández-Ramírez RU, Neugebauer RS, Leyden W, Althoff KN, Achenbach CJ, Hessol NA, Modur SP, D'Souza G, Bosch RJ, Grover S, Horberg MA, Kitahata MM, Mayor AM, Novak RM, Rabkin CS, Sterling TR, Goedert JJ, Justice AC, Engels EA, Moore RD, Silverberg MJ. Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 75: 382-390. PMID: 28394855, PMCID: PMC5490794, DOI: 10.1097/qai.0000000000001394.Peer-Reviewed Original ResearchConceptsT-cell countsKS riskCD4 countKaposi's sarcomaART useHIV-1 RNA viral loadNorth American AIDS Cohort CollaborationTime-updated Cox regressionCD4 T-cell countKaposi's sarcoma riskAntiretroviral therapy useRNA viral loadRecent CD4 countViral load measuresAssociation of CD4Cohort CollaborationKS etiologyRecent VLVL measuresAntiretroviral therapyHIV diagnosisIndependent predictorsTherapy useViral loadCox regression
2016
The Effect of Substance Use Disorders on the Association Between Guideline-concordant Long-term Opioid Therapy and All-cause Mortality
Gaither JR, Goulet JL, Becker WC, Crystal S, Edelman EJ, Gordon K, Kerns RD, Rimland D, Skanderson M, Justice AC, Fiellin DA. The Effect of Substance Use Disorders on the Association Between Guideline-concordant Long-term Opioid Therapy and All-cause Mortality. Journal Of Addiction Medicine 2016, 10: 418-428. PMID: 27610580, PMCID: PMC5083184, DOI: 10.1097/adm.0000000000000255.Peer-Reviewed Original ResearchConceptsSubstance use disordersLong-term opioid therapyCause mortalityOpioid therapySUD treatmentUse disordersLower mortalityTime-updated Cox regressionUntreated substance use disordersVeterans Aging Cohort StudyOpioid-prescribing guidelinesGuideline-concordant careSUD statusAging Cohort StudyClinical practice guidelinesSUD treatment servicesOverall sampleHIV patientsCohort studyCox regressionPractice guidelinesPatientsTreatment servicesHigh mortalityMortalityWeight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals
Herrin M, Tate JP, Akgün KM, Butt AA, Crothers K, Freiberg MS, Gibert CL, Leaf DA, Rimland D, Rodriguez-Barradas MC, Ruser CB, Herold KC, Justice AC. Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2016, 73: 228-236. PMID: 27171741, PMCID: PMC5023454, DOI: 10.1097/qai.0000000000001071.Peer-Reviewed Original ResearchConceptsRisk of DMVeterans Aging Cohort StudyAntiretroviral therapyAging Cohort StudyDiabetes mellitusBody mass indexUninfected individualsWeight gainART initiationIncident diabetesCohort studyHazard ratioMass indexIncident type 2 diabetes mellitusAvailable body mass indexBaseline body mass indexType 2 diabetes mellitusNational observational studyConfidence intervalsSubstantial weight gainHIV infectionCox regressionPounds of weightObservational studyLow prevalenceThe Association Between Receipt of Guideline-Concordant Long-Term Opioid Therapy and All-Cause Mortality
Gaither JR, Goulet JL, Becker WC, Crystal S, Edelman EJ, Gordon K, Kerns RD, Rimland D, Skanderson M, Justice AC, Fiellin DA. The Association Between Receipt of Guideline-Concordant Long-Term Opioid Therapy and All-Cause Mortality. Journal Of General Internal Medicine 2016, 31: 492-501. PMID: 26847447, PMCID: PMC4835362, DOI: 10.1007/s11606-015-3571-4.Peer-Reviewed Original ResearchConceptsSubstance use disordersGuideline-concordant careCause mortalityOpioid therapyLong-term opioid therapyUntreated substance use disordersCurrent substance use disorderTerm opioid therapyTime-updated covariatesPrimary care visitsImportant clinical outcomesMulti-modal treatmentUrine drug testingUninfected patientsUntreated patientsCare visitsChronic painClinical outcomesCox regressionDecreased riskHigh comorbidityMortality burdenRehabilitative therapySUD treatmentHigh risk
2015
Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients
Re V, Kallan MJ, Tate JP, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park LS, Dubrow R, Reddy KR, Kostman JR, Justice AC, Localio AR. Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. Open Forum Infectious Diseases 2015, 2: ofv109. PMID: 26284259, PMCID: PMC4536329, DOI: 10.1093/ofid/ofv109.Peer-Reviewed Original ResearchEnd-stage liver diseaseHIV/HCV-coinfected patientsRisk of ESLDHIV/HCV patientsHuman immunodeficiency virusFIB-4Antiretroviral therapyESLD riskHCV patientsLaboratory variablesLiver diseaseHuman immunodeficiency virus/hepatitis C virus‐coinfected patientsHepatitis C virus-coinfected patientsLiver-related deathRetrospective cohort studyRisk factor modificationPlatelet ratio indexDecision curve analysisVeterans Health AdministrationHCV treatment decisionsHepatic decompensationHCV treatmentCohort studyCox regressionImmunodeficiency virus
2014
Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery
Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N, EuroCoord F, Engsig F, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla P, Guest J, Samji H, Castagna A, Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher H, De Wit S, Burkholder G, Teira R, Justice A, Sterling T, Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle S, Sterne J, Boulle A, Brodt H, Casabona J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Fätkenheuer G, Gill J, Guest J, Haerry D, Hogg R, Justice A, Mocroft A, Obel N, Kitahata M, Lampe F, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Ingle S, May M, Sterne J, Zangerle R, Touloumi G, Warszawski J, Meyer L, Dabis F, Krause M, Ghosn J, Leport C, Reiss P, Wit F, Prins M, Bucher H, Sabin C, Gibb D, Fätkenheuer G, Del Amo J, Obel N, Thorne C, Mocroft A, Kirk O, Stephan C, Pérez-Hoyos S, Hamouda O, Gussenheimer-Bartmeyer B, Noguera-Julian A, Antinori A, Monforte A, Brockmeyer N, Ramos J, Battegay M, Rauch A, Mussini C, Tookey P, Casabona J, Miró J, Castagna A, de Wit S, Goetghebuer T, Torti C, Teira R, Garrido M, Judd A, Conejo P, Haerry D, Weller I, Casabona J, Costagliola D, d'Arminio-Monforte A, Battegay M, de Wit S, Del Amo J, Grarup J, Chêne G, Colin C, Schwimmer C, Termote M, Kjaer J, Campbell M, Raben D, Battegay M, Bohlius J, Bouteloup V, Bucher H, Cozzi-Lepri A, Dabis F, Monforte A, del Amo J, Dorrucci M, Egger M, Engsig F, Furrer H, Judd A, Kirk O, Lambotte O, Lewden C, Lodi S, Lodwick R, Matheron S, Meyer L, Miro J, Mocroft A, Monge S, Nakagawa F, Obel N, Paredes R, Phillips A, Puoti M, Reekie J, Sabin C, Scherrer A, Smit C, Sterne J, Thiebaut R, Thorne C, Torti C, Touloumi G, Wittkop L. Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases 2014, 58: 1312-1321. PMID: 24457342, PMCID: PMC6276895, DOI: 10.1093/cid/ciu038.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyIncomplete CD4 recoveryCD4 countLong-term mortalityHIV-positive individualsViral suppressionRisk factorsCD4 recoveryInitiation of cARTLow initial CD4 countsCD4 cell recoveryLow CD4 countSustained viral suppressionInitial CD4 countHuman immunodeficiency virusCause of deathDifferent patient groupsCART initiationAntiretroviral therapyHIV cohortCox regressionImmunodeficiency virusPatient groupEligible individualsSubsequent mortality
2013
Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States
Collaboration T, del Amo J, Jarrin I, May M, Dabis F, Crane H, Podzamczer D, Sterling T, Abgrall S, Lampe F, Justice A, Castagna A, Boesecke C, Staehelin C, De Wolf F, Guest J, Mugavero M, Khaykin P, Samji H, Ingle S, Sterne J, Gill M. Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States. Clinical Infectious Diseases 2013, 56: 1800-1809. PMID: 23457077, DOI: 10.1093/cid/cit111.Peer-Reviewed Original ResearchConceptsAdjusted mortality hazard ratioAntiretroviral therapyCause mortalityHazard ratioAIDS mortalityHuman immunodeficiency virus-positive subjectsLower mortalityNon-AIDS mortalityAfrican AmericansMortality hazard ratioVirus-positive subjectsAIDS mortality ratesCanadian First Nations peopleFirst Nations peopleCohort studyUS patientsCox regressionEuropean patientsHealthy migrantMortality ratePatientsHigh mortalityMortalityEthnicity/raceDeath rate
2009
Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America
Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD, Research and Design N. Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America. Clinical Infectious Diseases 2009, 49: 1582-1590. PMID: 19845473, PMCID: PMC2871149, DOI: 10.1086/644768.Peer-Reviewed Original ResearchConceptsPlasma HIV RNA levelsCombination antiretroviral therapyHIV RNA levelsVirologic failureRegimen failureHistory of AIDSAntiretroviral therapyTreatment failureHigher plasma HIV RNA levelsAbility of therapyRNA levelsT-cell countsTreatment-naive patientsIndependent risk factorMultivariate Cox regressionAggressive therapeutic interventionMore effective optionsModified therapyHIV infectionCox regressionRisk factorsT cellsSubsequent mortalityMortality rateClinical practice
2006
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis
May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. The Lancet 2006, 368: 451-458. PMID: 16890831, DOI: 10.1016/s0140-6736(06)69152-6.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyCD4 cell countAntiretroviral therapyHazard ratioTreatment responseTreatment-naive HIV-1-infected adultsCell countHIV-1-infected adultsMedian CD4 cell countHIV-1 RNA copiesCharacteristics of patientsHIV-1 RNAShort-term prognosisHIV treatment responseProportion of womenPrimary endpointVirological responseCohort studyHIV infectionCox regressionHAARTPatientsRNA copiesCorresponding figurePrognosis
1996
The role of functional status in predicting inpatient mortality with AIDS: A comparison with current predictors
Justice A, Aiken L, Smith H, Turner B. The role of functional status in predicting inpatient mortality with AIDS: A comparison with current predictors. Journal Of Clinical Epidemiology 1996, 49: 193-201. PMID: 8606320, DOI: 10.1016/0895-4356(95)00546-3.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeActivities of Daily LivingAdultCD4 Lymphocyte CountDiscriminant AnalysisFemaleHealth StatusHospital MortalityHumansLength of StayMalePredictive Value of TestsPrognosisProportional Hazards ModelsReproducibility of ResultsSeverity of Illness IndexUnited StatesUnited States Agency for Healthcare Research and QualityConceptsCD4 cell countInpatient mortalityCD4 countFunctional statusCell countHighest AIDS incidenceIndependent prognostic rolePercent of patientsHazard of deathLength of staySeverity classification systemHospital stayOverall mortalityPrognostic roleMortality predictorsCox regressionPrognostic stagingAIDS hospitalizationsDaily livingSeverity systemsMortality ratePatientsNursing assistanceAIDS incidenceMortality